Literature DB >> 32907476

Availability of Extended-Release Buprenorphine to Treat Opioid Use Disorders Among Medicaid-Covered Patients.

Chelsea L Shover1.   

Abstract

Entities:  

Keywords:  Drug abuse; Extended-release buprenorphine; Service delivery systems; Substance use disorder treatment

Mesh：

Substances：

Year:  2020        PMID： 32907476      PMCID： PMC7895448          DOI： 10.1176/appi.ps.202000165

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN： 1075-2730            Impact factor:   3.084


× No keyword cloud information.
  4 in total

1.  Medicaid coverage of medications to treat alcohol and opioid dependence.

Authors:  Tami L Mark; Robert Lubran; Elinore F McCance-Katz; Mady Chalk; John Richardson
Journal:  J Subst Abuse Treat       Date:  2015-04-16

2.  Insurance Financing Increased For Mental Health Conditions But Not For Substance Use Disorders, 1986-2014.

Authors:  Tami L Mark; Tracy Yee; Katharine R Levit; Jessica Camacho-Cook; Eli Cutler; Christopher D Carroll
Journal:  Health Aff (Millwood)       Date:  2016-06-01       Impact factor: 6.301

3.  Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Barbara R Haight; Susan M Learned; Celine M Laffont; Paul J Fudala; Yue Zhao; Amanda S Garofalo; Mark K Greenwald; Vijay R Nadipelli; Walter Ling; Christian Heidbreder
Journal:  Lancet       Date:  2019-02-18       Impact factor: 79.321

4.  Predictors of availability of long-acting medication for opioid use disorder.

Authors:  Chelsea L Shover; Keith Humphreys
Journal:  Drug Alcohol Depend       Date:  2019-09-25       Impact factor: 4.492
  4 in total
  1 in total

1.  Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.

Authors:  Jake R Morgan; Alexander Y Walley; Sean M Murphy; Avik Chatterjee; Scott E Hadland; Joshua Barocas; Benjamin P Linas; Sabrina A Assoumou
Journal:  Drug Alcohol Depend       Date:  2021-05-21       Impact factor: 4.852
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.